| Year |
Citation |
Score |
| 2024 |
Nouri M, Varkaris A, Ridinger M, Dalrymple SL, Dennehy CM, Isaacs JT, Einstein DJ, Brennen WN, Balk SP. AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate Cancer. Molecular Cancer Therapeutics. PMID 38894678 DOI: 10.1158/1535-7163.MCT-23-0933 |
0.445 |
|
| 2024 |
Caramella-Pereira F, Zheng Q, Hicks JL, Roy S, Jones T, Pomper M, Antony L, Meeker AK, Yegnasubramanian S, De Marzo AM, Brennen WN. Overexpression of Fibroblast Activation Protein (FAP) in stroma of proliferative inflammatory atrophy (PIA) and primary adenocarcinoma of the prostate. Medrxiv : the Preprint Server For Health Sciences. PMID 38633791 DOI: 10.1101/2024.04.04.24305338 |
0.479 |
|
| 2024 |
Pacheco-Torres J, Sharma RK, Mironchik Y, Wildes F, Brennen WN, Artemov D, Krishnamachary B, Bhujwalla ZM. Prostate fibroblasts and prostate cancer associated fibroblasts exhibit different metabolic, matrix degradation and PD-L1 expression responses to hypoxia. Frontiers in Molecular Biosciences. 11: 1354076. PMID 38584702 DOI: 10.3389/fmolb.2024.1354076 |
0.375 |
|
| 2024 |
Brennen WN, Le Magnen C, Karkampouna S, Anselmino N, Bock N, Choo N, Clark AK, Coleman IM, Dolgos R, Ferguson AM, Goode DL, Krutihof-de Julio M, Navone NM, Nelson PS, O'Neill E, et al. Defining the challenges and opportunities for using patient-derived models in prostate cancer research. The Prostate. PMID 38450798 DOI: 10.1002/pros.24682 |
0.471 |
|
| 2024 |
Mandl A, Jasmine S, Krueger T, Kumar R, Coleman IM, Dalrymple SL, Antony L, Rosen DM, Jing Y, Hanratty B, Patel RA, Jin-Yih L, Dias J, Celatka CA, Tapper AE, ... ... Brennen WN, et al. LSD1 inhibition suppresses ASCL1 and de-represses YAP1 to drive potent activity against neuroendocrine prostate cancer. Biorxiv : the Preprint Server For Biology. PMID 38328141 DOI: 10.1101/2024.01.17.576106 |
0.524 |
|
| 2023 |
Mori JO, Elhussin I, Brennen WN, Graham MK, Lotan TL, Yates CC, De Marzo AM, Denmeade SR, Yegnasubramanian S, Nelson WG, Denis GV, Platz EA, Meeker AK, Heaphy CM. Prognostic and therapeutic potential of senescent stromal fibroblasts in prostate cancer. Nature Reviews. Urology. PMID 37907729 DOI: 10.1038/s41585-023-00827-x |
0.671 |
|
| 2023 |
Patel RA, Sayar E, Coleman I, Roudier MP, Hanratty B, Low JY, Jaiswal N, Ajkunic A, Dumpit R, Ercan C, Salama N, O'Brien VP, Isaacs WB, Epstein JI, De Marzo AM, ... ... Brennen WN, et al. Characterization of HOXB13 expression patterns in localized and metastatic castration-resistant prostate cancer. The Journal of Pathology. PMID 37850574 DOI: 10.1002/path.6216 |
0.517 |
|
| 2023 |
Labrecque MP, Brown LG, Coleman IM, Nguyen HM, Dalrymple S, Brennen WN, Isaacs JT, Li D, Lakely B, DeLucia DC, Lee JK, Schweizer MT, Lin DW, Corey E, Nelson PS, et al. Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer. The Prostate. PMID 37796107 DOI: 10.1002/pros.24630 |
0.486 |
|
| 2023 |
Isaacs JT, Dalrymple SL, Antony L, Marc Rosen D, Coleman IM, Nelson PS, Kostova M, Murray IA, Perdew GH, Denmeade SR, Akinboye ES, Brennen WN. Third generation quinoline-3-carboxamide transcriptional disrupter of HDAC4, HIF-1α, and MEF-2 signaling for metastatic castration-resistant prostate cancer. The Prostate. PMID 37559436 DOI: 10.1002/pros.24606 |
0.633 |
|
| 2023 |
Pruitt HC, Guan Y, Liu H, Carey AE, Brennen WN, Lu J, Joshu C, Weeraratna A, Lotan TL, Karin Eisinger-Mathason TS, Gerecht S. Collagen VI Deposition Mediates Stromal T cell Trapping through Inhibition of T cell motility in the Prostate Tumor Microenvironment. Matrix Biology : Journal of the International Society For Matrix Biology. PMID 37331435 DOI: 10.1016/j.matbio.2023.06.002 |
0.399 |
|
| 2022 |
Sena LA, Kumar R, Sanin DE, Thompson EA, Rosen DM, Dalrymple SL, Antony L, Yang Y, Gomes-Alexandre C, Hicks JL, Jones T, Bowers KA, Eskra JN, Meyers J, Gupta A, ... ... Brennen WN, et al. Prostate cancer androgen receptor activity dictates efficacy of bipolar androgen therapy through MYC. The Journal of Clinical Investigation. PMID 36194476 DOI: 10.1172/JCI162396 |
0.669 |
|
| 2022 |
Sena LA, Brennen WN, Isaacs JT. There are gremlins in prostate cancer. Nature Cancer. 3: 530-531. PMID 35624340 DOI: 10.1038/s43018-022-00381-2 |
0.468 |
|
| 2021 |
Isaacs JT, Brennen WN, Christensen SB, Denmeade SR. Mipsagargin: The Beginning-Not the End-of Thapsigargin Prodrug-Based Cancer Therapeutics. Molecules (Basel, Switzerland). 26. PMID 34946547 DOI: 10.3390/molecules26247469 |
0.644 |
|
| 2021 |
Kumar R, Mendonca J, Owoyemi O, Boyapati K, Thomas N, Kanacharoen S, Coffey M, Topiwala D, Gomes C, Ozbek B, Jones T, Rosen M, Dong L, Wiens S, Brennen WN, et al. Supraphysiological testosterone induces ferroptosis and activates immune pathways through nucleophagy in prostate cancer. Cancer Research. PMID 34645612 DOI: 10.1158/0008-5472.CAN-20-3607 |
0.631 |
|
| 2021 |
Zhu Y, Dalrymple SL, Coleman I, Zheng SL, Xu J, Hooper JE, Antonarakis ES, De Marzo AM, Meeker AK, Nelson PS, Isaacs WB, Denmeade SR, Luo J, Brennen WN, Isaacs JT. Correction: Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. Oncogene. PMID 33958727 DOI: 10.1038/s41388-021-01805-6 |
0.589 |
|
| 2021 |
de Groot AE, Myers KV, Krueger TEG, Kiemen AL, Nagy NH, Brame A, Torres VE, Zhang Z, Trabzonlu L, Brennen WN, Wirtz D, De Marzo AM, Amend SR, Pienta KJ. Characterization of tumor-associated macrophages in prostate cancer transgenic mouse models. The Prostate. PMID 33949714 DOI: 10.1002/pros.24139 |
0.517 |
|
| 2021 |
Brennen WN, Zhu Y, Coleman IM, Dalrymple SL, Antony L, Patel RA, Hanratty B, Chikarmane R, Meeker AK, Zheng SL, Hooper JE, Luo J, De Marzo AM, Corey E, Xu J, et al. Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer. Jci Insight. PMID 33724955 DOI: 10.1172/jci.insight.146827 |
0.432 |
|
| 2021 |
Zhu Y, Dalrymple SL, Coleman I, Zheng SL, Xu J, Hooper JE, Antonarakis ES, De Marzo AM, Meeker AK, Nelson PS, Isaacs WB, Denmeade SR, Luo J, Brennen WN, Isaacs JT. Correction to: Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. Oncogene. PMID 33564077 DOI: 10.1038/s41388-021-01640-9 |
0.589 |
|
| 2020 |
Brennen WN, J Thorek DL, Jiang W, Krueger TE, Antony L, Denmeade SR, Isaacs JT. Overcoming stromal barriers to immuno-oncological responses via fibroblast activation protein-targeted therapy. Immunotherapy. PMID 33148078 DOI: 10.2217/imt-2020-0066 |
0.661 |
|
| 2020 |
Zhu Y, Dalrymple SL, Coleman I, Zheng SL, Xu J, Hooper JE, Antonarakis ES, De Marzo AM, Meeker AK, Nelson PS, Isaacs WB, Denmeade SR, Luo J, Brennen WN, Isaacs JT. Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. Oncogene. PMID 32989253 DOI: 10.1038/s41388-020-01479-6 |
0.547 |
|
| 2020 |
Rogers OC, Antony L, Levy O, Joshi N, Simons BW, Dalrymple S, Rosen M, Pickering A, Lan H, Kuang H, Ranganath SH, Zheng L, Karp JM, Howard SP, Denmeade SR, ... ... Brennen WN, et al. Microparticle Encapsulation of a Prostate-Targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-Resistant Prostate Cancer. Molecular Cancer Therapeutics. PMID 32943549 DOI: 10.1158/1535-7163.Mct-20-0227 |
0.704 |
|
| 2020 |
Eskra JN, Rabizadeh D, Mangold L, Fabian E, Brennen WN, Yeater DB, Pienta KJ, Partin AW, Isaacs WB, Pavlovich CP, Luo J. A novel method for detection of exfoliated prostate cancer cells in urine by RNA in situ hybridization. Prostate Cancer and Prostatic Diseases. PMID 32820256 DOI: 10.1038/S41391-020-00272-6 |
0.433 |
|
| 2020 |
Simons BW, Dalrymple S, Rosen M, Zheng L, Brennen WN. A hemi-spleen injection model of liver metastasis for prostate cancer. The Prostate. PMID 32761950 DOI: 10.1002/pros.24055 |
0.411 |
|
| 2020 |
Low JY, Brennen WN, Meeker AK, Ikonen E, Simons BW, Laiho M. Stromal CAVIN1 controls prostate cancer microenvironment and metastasis by modulating lipid distribution and inflammatory signaling. Molecular Cancer Research : McR. PMID 32493699 DOI: 10.1158/1541-7786.Mcr-20-0364 |
0.472 |
|
| 2019 |
Isaacs JT, Brennen WN, Denmeade SR. Serial bipolar androgen therapy (sBAT) using cyclic supraphysiologic testosterone (STP) to treat metastatic castration-resistant prostate cancer (mCRPC). Annals of Translational Medicine. 7: S311. PMID 32016030 DOI: 10.21037/Atm.2019.10.32 |
0.653 |
|
| 2019 |
Hughes RM, Simons BW, Khan H, Miller R, Kugler V, Torquato S, Theodros D, Haffner MC, Lotan TL, Huang J, Davicioni E, An SS, Riddle RC, Thorek DL, Garraway IP, ... ... Brennen WN, et al. Asporin Restricts Mesenchymal Stromal Cell Differentiation, Alters the Tumor Microenvironment, and Drives Metastatic Progression. Cancer Research. PMID 31123087 DOI: 10.1158/0008-5472.Can-18-2931 |
0.39 |
|
| 2019 |
Brennen WN, Schweizer MT, Wang H, Bivalacqua TJ, Partin AW, Lim SJ, Chapman C, Abdallah R, Levy O, Bhowmick NA, Karp JM, De Marzo A, Isaacs JT, Denmeade SR. In Reply to the Letter to the Editor from Raj et al.: Clinical Evidence Indicates Allogeneic Mesenchymal Stem Cells Do Not Pose a Significant Risk for Cancer Progression in the Context of Cell-Based Drug Delivery. Stem Cells Translational Medicine. PMID 30925030 DOI: 10.1002/Sctm.19-0068 |
0.494 |
|
| 2019 |
Akinboye ES, Brennen WN, Denmeade SR, Isaacs JT. Albumin-linked prostate-specific antigen-activated thapsigargin- and niclosamide-based molecular grenades targeting the microenvironment in metastatic castration-resistant prostate cancer. Asian Journal of Urology. 6: 99-108. PMID 30775253 DOI: 10.1016/J.Ajur.2018.11.004 |
0.697 |
|
| 2019 |
Schweizer MT, Wang H, Bivalacqua TJ, Partin AW, Lim SJ, Chapman C, Abdallah R, Levy O, Bhowmick NA, Karp JM, De Marzo A, Isaacs JT, Brennen WN, Denmeade SR. A Phase I Study to Assess the Safety and Cancer-Homing Ability of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Men with Localized Prostate Cancer. Stem Cells Translational Medicine. PMID 30735000 DOI: 10.1002/Sctm.18-0230 |
0.599 |
|
| 2018 |
Krueger TE, Thorek DLJ, Meeker AK, Isaacs JT, Brennen WN. Tumor-infiltrating mesenchymal stem cells: Drivers of the immunosuppressive tumor microenvironment in prostate cancer? The Prostate. PMID 30488530 DOI: 10.1002/Pros.23738 |
0.544 |
|
| 2018 |
Brennen WN, Isaacs JT. Mesenchymal stem cells and the embryonic reawakening theory of BPH. Nature Reviews. Urology. PMID 30214054 DOI: 10.1038/S41585-018-0087-9 |
0.322 |
|
| 2018 |
Navone NM, van Weerden WM, Vessella RL, Williams ED, Wang Y, Isaacs JT, Nguyen HM, Culig Z, van der Pluijm G, Rentsch CA, Marques RB, de Ridder CMA, Bubendorf L, Thalmann GN, Brennen WN, et al. Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models. The Prostate. PMID 30073676 DOI: 10.1002/Pros.23701 |
0.444 |
|
| 2018 |
Krueger TEG, Thorek DLJ, Denmeade SR, Isaacs JT, Brennen WN. Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise. Stem Cells Translational Medicine. PMID 30070053 DOI: 10.1002/Sctm.18-0024 |
0.577 |
|
| 2018 |
Rogers OC, Anthony L, Rosen DM, Brennen WN, Denmeade SR. PSA-selective activation of cytotoxic human serine proteases within the tumor microenvironment as a therapeutic strategy to target prostate cancer. Oncotarget. 9: 22436-22450. PMID 29854290 DOI: 10.18632/Oncotarget.25091 |
0.72 |
|
| 2018 |
Kostova MB, Brennen WN, Lopez D, Anthony L, Wang H, Platz E, Denmeade SR. PSA-alpha-2-macroglobulin complex is enzymatically active in the serum of patients with advanced prostate cancer and can degrade circulating peptide hormones. The Prostate. PMID 29659051 DOI: 10.1002/Pros.23539 |
0.668 |
|
| 2018 |
Brennen WN, Isaacs JT. The what, when, and why of human prostate cancer xenografts. The Prostate. PMID 29575112 DOI: 10.1002/Pros.23510 |
0.471 |
|
| 2017 |
Brennen WN, Isaacs JT. Cellular Origin of Androgen Receptor Pathway-Independent Prostate Cancer and Implications for Therapy. Cancer Cell. 32: 399-401. PMID 29017052 DOI: 10.1016/J.Ccell.2017.09.011 |
0.451 |
|
| 2017 |
Isaacs JT, Brennen WN, Denmeade SR. Rationale for Bipolar Androgen Therapy (BAT) for Metastatic Prostate Cancer. Cell Cycle (Georgetown, Tex.). 0. PMID 28820291 DOI: 10.1080/15384101.2017.1360645 |
0.656 |
|
| 2017 |
Brennen WN, Zhang B, Kulac I, Kisteman LN, Antony L, Wang H, Meeker AK, De Marzo AM, Garraway IP, Denmeade SR, Isaacs JT. Mesenchymal stem cell infiltration during neoplastic transformation of the human prostate. Oncotarget. PMID 28493842 DOI: 10.18632/Oncotarget.17362 |
0.642 |
|
| 2016 |
Levy O, Brennen WN, Han E, Rosen DM, Musabeyezu J, Safaee H, Ranganath S, Ngai J, Heinelt M, Milton Y, Wang H, Bhagchandani SH, Joshi N, Bhowmick N, Denmeade SR, et al. A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer. Biomaterials. 91: 140-150. PMID 27019026 DOI: 10.1016/J.Biomaterials.2016.03.023 |
0.662 |
|
| 2016 |
Akinboye ES, Brennen WN, Rosen DM, Bakare O, Denmeade SR. Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy. The Prostate. PMID 26835873 DOI: 10.1002/Pros.23162 |
0.678 |
|
| 2016 |
Brennen WN, Kisteman LN, Isaacs JT. Rapid selection of mesenchymal stem and progenitor cells in primary prostate stromal cultures. The Prostate. PMID 26732992 DOI: 10.1002/Pros.23145 |
0.415 |
|
| 2016 |
Akinboye ES, Brennen WN, Rosen DM, Bakare O, Denmeade SR. Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy Prostate. DOI: 10.1002/pros.23162 |
0.495 |
|
| 2014 |
Brennen WN, Rosen DM, Chaux A, Netto GJ, Isaacs JT, Denmeade SR. Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)-activated prodrug in murine xenograft models of human cancer. The Prostate. 74: 1308-19. PMID 25053236 DOI: 10.1002/Pros.22847 |
0.56 |
|
| 2014 |
Brennen WN, Drake CG, Isaacs JT. Enhancement of the T-cell armamentarium as a cell-based therapy for prostate cancer. Cancer Research. 74: 3390-5. PMID 24747912 DOI: 10.1158/0008-5472.Can-14-0249 |
0.452 |
|
| 2013 |
Brennen WN, Denmeade SR, Isaacs JT. Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment. Endocrine-Related Cancer. 20: R269-90. PMID 23975882 DOI: 10.1530/Erc-13-0151 |
0.613 |
|
| 2013 |
Brennen WN, Chen S, Denmeade SR, Isaacs JT. Quantification of Mesenchymal Stem Cells (MSCs) at sites of human prostate cancer. Oncotarget. 4: 106-17. PMID 23362217 DOI: 10.18632/Oncotarget.805 |
0.614 |
|
| 2013 |
Isaacs JT, Antony L, Dalrymple SL, Brennen WN, Gerber S, Hammers H, Wissing M, Kachhap S, Luo J, Xing L, Björk P, Olsson A, Björk A, Leanderson T. Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment. Cancer Research. 73: 1386-99. PMID 23149916 DOI: 10.1158/0008-5472.Can-12-2730 |
0.452 |
|
| 2012 |
Brennen WN, Rosen DM, Wang H, Isaacs JT, Denmeade SR. Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug. Journal of the National Cancer Institute. 104: 1320-34. PMID 22911669 DOI: 10.1093/Jnci/Djs336 |
0.562 |
|
| 2012 |
Denmeade SR, Mhaka AM, Rosen DM, Brennen WN, Dalrymple S, Dach I, Olesen C, Gurel B, Demarzo AM, Wilding G, Carducci MA, Dionne CA, Møller JV, Nissen P, Christensen SB, et al. Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. Science Translational Medicine. 4: 140ra86. PMID 22745436 DOI: 10.1126/Scitranslmed.3003886 |
0.749 |
|
| 2012 |
Brennen WN, Isaacs JT, Denmeade SR. Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Molecular Cancer Therapeutics. 11: 257-66. PMID 22323494 DOI: 10.1158/1535-7163.Mct-11-0340 |
0.608 |
|
| 2012 |
Denmeade SR, Mhaka AM, Rosen DM, Brennen WN, Dalrymple S, Dach I, Olesen C, Gurel B, DeMarzo AM, Wilding G, Carducci MA, Dionne CA, Møller JV, Nissen P, Christensen SB, et al. Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy (Science Translational Medicine) Science Translational Medicine. 4. DOI: 10.1126/Scitranslmed.3004546 |
0.747 |
|
| 2009 |
LeBeau AM, Brennen WN, Aggarwal S, Denmeade SR. Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin. Molecular Cancer Therapeutics. 8: 1378-86. PMID 19417147 DOI: 10.1158/1535-7163.Mct-08-1170 |
0.759 |
|
| 2008 |
Aggarwal S, Brennen WN, Kole TP, Schneider E, Topaloglu O, Yates M, Cotter RJ, Denmeade SR. Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sites. Biochemistry. 47: 1076-86. PMID 18095711 DOI: 10.1021/Bi701921B |
0.638 |
|
| 2006 |
Aggarwal S, Cole T, Brennen W, Topaloglu O, Schneider E, Cotter R, Denmeade S. 527 POSTER Fibroblast Activation Protein (FAP) activated anti-stromal prodrug therapy for cancer European Journal of Cancer Supplements. 4: 160. DOI: 10.1016/S1359-6349(06)70532-8 |
0.576 |
|
| 2004 |
Brennen WN, Cooper CR, Capitosti S, Brown ML, Sikes RA. Thalidomide and analogues: current proposed mechanisms and therapeutic usage. Clinical Prostate Cancer. 3: 54-61. PMID 15279692 DOI: 10.3816/Cgc.2004.N.014 |
0.443 |
|
| 2003 |
Sikes RA, Walls AM, Brennen WN, Anderson JD, Choudhury-Mukherjee I, Schenck HA, Brown ML. Therapeutic approaches targeting prostate cancer progression using novel voltage-gated ion channel blockers. Clinical Prostate Cancer. 2: 181-7. PMID 15040863 DOI: 10.3816/Cgc.2003.N.028 |
0.487 |
|
| Show low-probability matches. |